OPT -80-206: A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of fidaxomicin Oral Suspension or Tablets in Pediatric Subjects with Clostridium

Project: Research project

Project Details

StatusFinished
Effective start/end date11/1/1210/31/13

Funding

  • Optimer Pharmaceuticals, Inc. (OPT-80-206)
  • Optimer Pharmaceuticals, Inc. (OPT-80-206)